Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Lantheus Holdings Inc LNTH

Healthcare Drug Manufacturers - Specialty & Generic
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a... see more

Recent & Breaking News (NDAQ:LNTH)

Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

ACCESS Newswire April 2, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Shareholders to Inquire about Securities Investigation

ACCESS Newswire March 31, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Connect

ACCESS Newswire March 29, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Reach Out

ACCESS Newswire March 26, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation

ACCESS Newswire March 24, 2026

Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

ACCESS Newswire March 22, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect

ACCESS Newswire March 19, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

GlobeNewswire March 17, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation

ACCESS Newswire March 17, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation

ACCESS Newswire March 15, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation

ACCESS Newswire March 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Investors to Inquire about Securities Investigation

ACCESS Newswire March 10, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Reach Out

ACCESS Newswire March 8, 2026

Lantheus Announces FDA Approval of PYLARIFY TruVu(TM) (piflufolastat F 18) Injection

GlobeNewswire March 6, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Reach Out

ACCESS Newswire March 5, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect

ACCESS Newswire March 3, 2026

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Business Wire March 2, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

GlobeNewswire March 2, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire February 26, 2026

Lantheus to Present at March 2026 Investor Conferences

GlobeNewswire February 24, 2026

Podcasts